ZA200502700B - 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. - Google Patents

1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. Download PDF

Info

Publication number
ZA200502700B
ZA200502700B ZA200502700A ZA200502700A ZA200502700B ZA 200502700 B ZA200502700 B ZA 200502700B ZA 200502700 A ZA200502700 A ZA 200502700A ZA 200502700 A ZA200502700 A ZA 200502700A ZA 200502700 B ZA200502700 B ZA 200502700B
Authority
ZA
South Africa
Prior art keywords
optionally substituted
hydrogen
oxo
group
substituents
Prior art date
Application number
ZA200502700A
Other languages
English (en)
Inventor
Birgit Bollbuck
Joerg Eder
Richard Heng
Laszlo Revesz
Achim Schlapbach
Rudolf Waelchli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200502700B publication Critical patent/ZA200502700B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200502700A 2002-10-25 2005-04-04 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives. ZA200502700B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0224917.5A GB0224917D0 (en) 2002-10-25 2002-10-25 Organic compounds

Publications (1)

Publication Number Publication Date
ZA200502700B true ZA200502700B (en) 2006-05-31

Family

ID=9946616

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200502700A ZA200502700B (en) 2002-10-25 2005-04-04 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives.

Country Status (19)

Country Link
US (1) US7645760B2 (fr)
EP (1) EP1558594A2 (fr)
JP (1) JP2006505575A (fr)
KR (1) KR20050065620A (fr)
CN (2) CN101570517A (fr)
AR (1) AR043055A1 (fr)
AU (1) AU2003296559B2 (fr)
BR (1) BR0315662A (fr)
CA (1) CA2502633C (fr)
EC (1) ECSP055745A (fr)
GB (1) GB0224917D0 (fr)
MX (1) MXPA05004348A (fr)
NO (1) NO20052487D0 (fr)
PE (1) PE20040779A1 (fr)
PL (1) PL374893A1 (fr)
RU (1) RU2347782C2 (fr)
TW (1) TW200420545A (fr)
WO (1) WO2004037796A2 (fr)
ZA (1) ZA200502700B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
SE0400441D0 (sv) 2004-02-25 2004-02-25 Active Biotech Ab Novel Benzofurans and Indols
SE0400440D0 (sv) * 2004-02-25 2004-02-25 Active Biotech Ab Novel Cinnamic Amides
GB0409236D0 (en) * 2004-04-26 2004-05-26 Novartis Ag Organic compounds
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
CN101007794B (zh) * 2006-01-26 2010-09-01 中国科学院上海药物研究所 N,n'-二取代哌嗪类衍生物及其制备方法、药物组合物和用途
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
WO2008090357A2 (fr) * 2007-01-24 2008-07-31 Palatin Technologies, Inc. Composés à base de pipérazine spécifiques du récepteur de la mélanocortine
TWI433838B (zh) 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
PT2528897E (pt) * 2010-01-29 2014-11-12 Otsuka Pharma Co Ltd Derivados de piridina dissubstituída como anticancerígenos
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
JP6014144B2 (ja) * 2012-08-08 2016-10-25 田辺三菱製薬株式会社 １，４−ベンゾオキサジン化合物の製法
US9993497B2 (en) * 2012-12-30 2018-06-12 Hadasit Medical Research Services And Development Ltd. Use of alginate compositions in preventing or reducing liver damage caused by a hepatotoxic agent
PE20160521A1 (es) * 2013-07-18 2016-05-20 Novartis Ag Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
US9776979B2 (en) * 2013-09-26 2017-10-03 Sanford-Burnham Medical Research Institute EBI2 modulators
BR112017015455A2 (pt) 2015-01-20 2018-01-23 Novartis Ag agentes de imagiologia pet
WO2021102359A2 (fr) * 2019-11-22 2021-05-27 The Regents Of The University Of California Inhibiteurs de taspase1 et leurs utilisations
WO2021105115A1 (fr) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Aminoquinolones substituées utilisées en tant qu'inhibiteurs de dgkalpha pour activation immunitaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60139646A (ja) * 1983-12-27 1985-07-24 Otsuka Pharmaceut Factory Inc ナフタレン誘導体
JPS6219577A (ja) * 1985-07-16 1987-01-28 Kanebo Ltd 新規なベンジルピペラジン誘導体および該化合物を有効成分とする医薬組成物
US5380726A (en) * 1993-01-15 1995-01-10 Ciba-Geigy Corporation Substituted dialkylthio ethers
FR2725445B1 (fr) * 1994-10-10 1996-10-31 Adir Nouveaux derives a structure 1-arylalkenyl 4-aryl alkyl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2000086603A (ja) 1998-07-15 2000-03-28 Yoshitomi Pharmaceut Ind Ltd 桂皮酸アミド誘導体および３―フェニルプロピオン酸アミド誘導体
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
IL160974A0 (en) * 2001-10-22 2004-08-31 Pfizer Prod Inc Piperazine derivatives with ccr1 receptor antagonist activity

Also Published As

Publication number Publication date
CN101570517A (zh) 2009-11-04
RU2005115964A (ru) 2006-01-27
MXPA05004348A (es) 2005-08-02
CN100554257C (zh) 2009-10-28
GB0224917D0 (en) 2002-12-04
CA2502633C (fr) 2011-02-01
CA2502633A1 (fr) 2004-05-06
WO2004037796A3 (fr) 2004-06-17
KR20050065620A (ko) 2005-06-29
TW200420545A (en) 2004-10-16
NO20052487L (no) 2005-05-24
BR0315662A (pt) 2005-08-30
EP1558594A2 (fr) 2005-08-03
AU2003296559B2 (en) 2007-11-01
CN1708489A (zh) 2005-12-14
PL374893A1 (en) 2005-11-14
US7645760B2 (en) 2010-01-12
JP2006505575A (ja) 2006-02-16
WO2004037796A2 (fr) 2004-05-06
RU2347782C2 (ru) 2009-02-27
US20060173004A1 (en) 2006-08-03
PE20040779A1 (es) 2004-12-21
ECSP055745A (es) 2005-07-06
AU2003296559A1 (en) 2004-05-13
AR043055A1 (es) 2005-07-13
NO20052487D0 (no) 2005-05-24

Similar Documents

Publication Publication Date Title
ZA200502700B (en) 1-(4-benzyl-piperazin-1-YL)-3-phenyl-propenone derivatives.
AU715841B2 (en) 3-spiro-indolin-2-one derivatives as vasopressin and/or oxytocin receptor ligands
JP4057244B2 (ja) 細胞接着阻害抗炎症および免疫抑制化合物
DE69431974T2 (de) Benzamid-Derivate und ihre Verwendung als Vasopressin-Antagonisten
CA1109867A (fr) Synthese des 2-one-1,4-diazacycloalcanes
US4954502A (en) 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
KR100307050B1 (ko) 신규피라졸유도체,그의제조방법및그를함유하는제약학적조성물
AU774564B2 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US20060135561A1 (en) 4-Aminopiperidine derivatives
US20090048264A1 (en) Piperazine amide derivatives
DE69417427T2 (de) Indol- und indolin-derivate als 5ht1d rezeptor antagonisten
JP2006505575A5 (fr)
CA2095847A1 (fr) 4-arylpiperazines et 4-arylpiperidines nouveaux
IE914293A1 (en) N-substituted lactams useful as cholecystokinin antagonists
JP3254205B2 (ja) タキキニンアンタゴニストとしての３−アゼチジニルアルキルピペリジンまたは−ピロリジン
WO2004113301A1 (fr) Inhibiteurs de transporteurs de glyt1 et leurs utilisations dans le traitement de troubles neurologiques et neuropsychiatriques
US20110092698A1 (en) Novel heterocyclyl compounds
CA2450271A1 (fr) Nouveaux analogues de phenylalkyl diamine et d'amide
JP3161892B2 (ja) インドール−７−カルボキサミド誘導体
US5585374A (en) Amide derivatives
US6878700B1 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
US5314885A (en) Cyclic benzylamino, benzylamido, and benzylimido antipsychotic agents
CA2189964A1 (fr) Nouveau derive de diaminomethylidene
US20040116518A1 (en) Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
JP2918508B2 (ja) アゼチジン類